Itolizumab, a monoclonal antibody developed by the Center of Molecular Immunology (CIM) in collaboration with Biocon, India’s largest pharmaceutical company, received authorization to begin...
Two more drugs, CIGB-258 and Itolizumab (Anti-CD6), manufactured by the Center for Genetic Engineering and Biotechnology (CIGB) have been added to Cuba’s arsenal of...